Table 1.

Characteristics of reports of therapeutic PDT.

Author	Year	Region	Photosensitizer	Administration	No. of cases	Included patients	post-BCG (%)	Tis (%)	Light energy (J/cm2)
Benson (16)	1986	USA	Photofrin	Intravenous	10	Multifocal Tis	0	10/10	24-45
D’Hallewin (18)	1995	Belgium	Photofrin	Intravenous	15	Multifocal Tis	3/15	15/15	75-100
D’Hallewin (19)	1997	Belgium	5-ALA	Intravesical	6	Recurrent Tis	6/6	6/6	75
Kriegmair (22)	1995	Germany	Photofrin	Intravenous	21	Recurrent, multifocal NMIBC	NA	5/21	15-30
Kriegmair (21)	1996	Germany	5-ALA	Intravesical	10	Recurrent NMIBC	10/10	4/10	15-60
Manyak (26)	2003	USA	Photofrin	Intravenous	34	Recurrent NMIBC	30/34	29/34	20-25
Naito (27)	1991	Japan	Photofrin	Intravenous	35	Recurrent NMIBC	NA	29/35	10-30
Nseyo (28)	2003	USA	Photofrin	Intravenous	5	Recurrent NMIBC	NA	2/5	10-60
Nseyo (29)	1998	USA	Photofrin	Intravenous	39	Recurrent NMIBC	Most	20/39	10-60
Nseyo (30)	1998	USA	Photofrin	Intravenous	36	Recurrent Tis	36/36	36/36	15
Shumaker (31)	1986	UK	Photofrin	Intravenous	14	Recurrent Tis	NA	14/14	15-25
Uchibayashi (36)	1995	Japan	Photofrin	Intravenous	34	Recurrent Tis	NA	34/34	NA
Unsöld (37)	1990	Germany	Photofrin	Intravenous	20	Recurrent Tis	NA	20/20	15-70
Waidelich (38)	2003	Germany	5-ALA	Intravesical	11	Recurrent, multifocal NMIBC	NA	9/11	100
Walther (40)	1997	USA	Photofrin	Intravenous	20	Recurrent NMIBC	5/20	6/20	16.5-25.6
Windahl (41)	1993	Sweden	Photofrin	Intravenous	10	Refractory NMIBC	1/10	8/10	15-53
Szygula (35)	2001	Poland	5-ALA	intravesical	12	NMIBC	NA	5/12	10

Tis, Tumor in situ; 5-ALA, 5-aminolevulinic acid; NMIBC, Non-muscle-invasive bladder cancer.